Industry

— Combines NewAmsterdam’s lead clinical program obicetrapib with Menarini’s deep cardiovascular disease and regional expertise — — Total deal value of over €1 billion; including €142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net product sales in Europe — — Obicetrapib is a next-generation oral, low-dose and once-daily … [Read more…]

— Additional Phase 2b data evaluating AD109 as potential treatment for OSA anticipated in Q3 2022 — AD109 Phase 3 development program expected to be initiated in late 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that the … [Read more…]

GYANT’s AI-powered virtual assistant will be used to automate patient intake for more efficient engagements between providers and patients SAN FRANCISCO–(BUSINESS WIRE)–GYANT, the patient journey automation company, today announced that its automated patient intake and charting tool, Intake, will be launched with Walmart Health Virtual Care, formerly known as MeMD. GYANT’s web-enabled clinical assessment solution … [Read more…]

Cheshire-based site to bolster plasmid DNA manufacturing, supporting cell and gene therapy development WILMINGTON, Mass. & MACCLESFIELD, England–(BUSINESS WIRE)–$CRL #LIFEatCRL–Charles River Laboratories International, Inc. (NYSE: CRL) announced today the opening of its High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. The expansion follows Charles River’s acquisition … [Read more…]

– Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed – – Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights – – Palleon receives upfront payment and is eligible for up to $196.5 million in … [Read more…]

Phase 1 Clinical Trial in Patients with Advanced B-Cell Malignancies Expected to Begin in the Second Half of 2022 NEW YORK–(BUSINESS WIRE)–Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application … [Read more…]

Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and potential dose response Topline Phase 2 data readout expected in February 2023 with interim results … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–Mountain Group Partners (“Mountain Group” or the “Firm”), a Nashville-based venture capital firm, announced the closing of an above target amount of $128 million in its third fund (“MGP Fund III”). Mountain Group will continue its strategy of investing in early-stage companies within human and animal life sciences and disruptive technologies. “We are … [Read more…]

Dr. Huang brings more than 30 years of biopharma experience, most recently as Chief Executive Officer and President of Flagship Pioneering start-up Cygnal Therapeutics Dunad appoints new CEO as company establishes U.S. operations, continues to expand its platform based on novel insights into covalent chemistry and build its internal drug discovery programs CAMBRIDGE, England–(BUSINESS WIRE)–Dunad … [Read more…]

Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results Priovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting … [Read more…]